The board of directors of Simcere Pharmaceutical Group Limited announced that, on November 21, 2023, the Group entered into an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited (Xiang Gang Kang Nai De Sheng Wu Yi Yao You Xian Gong Si) ("Connect Biopharma") in relation to Rademikibart (the "Product"), an innovative IL-4Ra monoclonal antibody. Pursuant to the Agreement, the Group will obtain the exclusive rights in relation to the development, manufacturing and commercialization of all indications of the Product in Greater China (the " Territory"). Connect Biopharma will retain its rights in respect of the Product outside the Territory and will continue to be responsible for and complete the ongoing clinical trials of the Product.

The Group will be independently responsible for conducting future clinical trials and developing new indications of the Product in the Territory. According to the terms of the Agreement, Connect Biopharma will receive an upfront payment of RMB 150 million (approximately USD 21 million), up to RMB875 million (approximately USD 125 million) upon achieving certain development and commercial milestones, and additional royalties up to low double-digit percentages of net sales. Rademikibart (CBP-201) is a fully human monoclonal antibody targeting IL-4Ra, a common subunit of IL-4 receptor and IL-13 receptor.

By binding with IL-4R, Rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the Th2 inflammatory pathway, thus achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis and asthma. Currently, Rademikibart is being simultaneously tested in the pivotal clinical trial and other related clinical trials for atopic dermatitis in China, and a phase II clinical trial for asthma globally.